(Q38149290)

29 August 2017

title

Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed (English)

1 reference

29 August 2017

1 reference

1 reference

Elena Di Gennaro

2

0 references

Alfredo Budillon

object named as

Alfredo Budillon

5

0 references

Antonio Avallone

object named as

Antonio Avallone

1

0 references

author name string

Lucrezia Silvestro

3

1 reference

29 August 2017

Vincenzo Rosario Iaffaioli

4

1 reference

29 August 2017

language of work or name

English

0 references

publication date

5 October 2013

1 reference

Expert Opinion on Drug Safety

29 August 2017

published in

1 reference

29 August 2017

volume

13

1 reference

29 August 2017

issue

1

1 reference

29 August 2017

page(s)

113-129

1 reference

Estimates of cancer incidence and mortality in Europe in 2008.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Tomudex (ZD1694): from concept to care, a programme in rational drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

5-Fluorouracil: mechanisms of action and clinical strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Preclinical and clinical aspects of biomodulation of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Clinical and preclinical pharmacokinetics of raltitrexed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Mature results from three large controlled studies with raltitrexed ('Tomudex').

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Raltitrexed: optimism and reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Lessons learned from raltitrexed--quality assurance, patient education and intensive supportive drugs to optimise tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Oxaliplatin: a review of preclinical and clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Role of oxaliplatin in the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Irinotecan and raltitrexed: an active combination in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Multidisciplinary approach to rectal cancer: are we ready for selective treatment strategies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Preoperative chemoradiation with raltitrexed ('Tomudex') for T2/N+ and T3/N+ rectal cancers: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Chemoradiation with raltitrexed (Tomudex) in preoperative treatment of stage II-III resectable rectal cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Impact of age and comorbidities on the treatment of gastrointestinal malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.845167

10.1517/14740338.2014.845167

21 January 2018

Identifiers

DOI

1 reference

release_osa5phdy7zexrlnhlerldrg4h4

29 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/osa5phdy7zexrlnhlerldrg4h4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference